teaser
The Committee for Medicinal Products for Human Use of the EMEA has recommended the adoption of a new indication for bevacizumab (Avastin).
It is the following: “Avastin in combination with interferon alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell cancer.”
Detailed recommendations for the use of this product will be described in the summary of product characteristics which will be available after the variation to the marketing authorisation has been granted by the European Commission.
